RxDoctor Payments Data

Marwan Edris, MD

Internal Medicine · Laguna Hills, CANPI 1013045970

Payments from drug & device makers

$127,622in general payments, 2019–2025

Across 58 payments — averaging $2200.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$79K
  • AstraZeneca$27K
  • Chiesi USA, Inc.$9K
  • AbbVie$7K
  • Gilead$5K
  • Novartis$594
  • plus $383 from 4 others
$10,369in research payments, 2019–2025

Across 17 payments — averaging $609.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vifor (international) Ltd.$8K
  • Gilead$2K

What the payments were for

  • Food & beverage$447100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$127,622 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$87,889
Medicare patients
136
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate60$80,380
EliquisApixaban56$76,296
OzempicSemaglutide58$75,380
JardianceEmpagliflozin18$29,362
MyrbetriqMirabegron27$28,115
XareltoRivaroxaban13$21,564
Breo ElliptaFluticasone/Vilanterol19$11,335
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$5,176
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen118$3,648
Diclofenac Sodium146$3,586
Levothyroxine Sodium209$3,143
SynthroidLevothyroxine Sodium35$3,102
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,573
Wixela InhubFluticasone Propion/Salmeterol19$2,467
Tamsulosin Hcl152$2,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$153$28,11527 claims
AbbVieSynthroid$7,052$3,10235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →